Physician profile
Davida D Rixter
NPI 1215193990
$11,413.88
in general payments reported to CMS, 2019-2025
27 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,291 · 2020: $431 · 2021: $863 · 2022: $386 · 2023: $809 · 2024: $402 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $5,977.11 | 2019-2021 | |
| Abbott Laboratories | $1,424.58 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $1,353.50 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $963.74 | 2022-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $581.95 | 2019-2025 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $159.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.10 | 2019-2025 | Relistor |
| Azurity Pharmaceuticals, INC. | $121.44 | 2023-2025 | Horizant, Horizant |
| Pfizer INC. | $119.10 | 2019-2025 | |
| Lilly USA, LLC | $98.95 | 2019 | |
| Abbvie INC. | $72.76 | 2022-2024 | Ubrelvy, Qulipta |
| Stimwave Technologies Incorporated | $72.19 | 2019 | |
| Ge Healthcare | $43.19 | 2021 | |
| Idorsia Pharmaceuticals US INC | $40.47 | 2023-2024 | Quviviq |
| Bioventus LLC | $30.31 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.71 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $26.27 | 2023 | Iovera |
| Assertio Therapeutics, INC. | $24.12 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.21 | 2019 | |
| Nevro Corp. | $21.90 | 2019 | |
| Valinor Pharma, LLC | $18.49 | 2025 | Movantik |
| Pernix Therapeutics Holdings, INC. | $17.64 | 2019 | |
| Currax Pharmaceuticals LLC | $16.59 | 2022 | |
| Mdd US Operations, LLC | $15.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2019 | |
| Almatica Pharma LLC | $11.65 | 2022 | |
| Fidia Pharma USA INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davida Rixter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.